Meningococcal Disease: Changes in Epidemiology and Prevention

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Specialty Public Health

Date 2012 Oct 17

PMID 23071402

Citations 66

Authors

Qiuzhi Chang

Yih-Ling Tzeng

David S Stephens

Affiliations

Soon will be listed here.

Abstract

The human bacterial pathogen Neisseria meningitidis remains a serious worldwide health threat, but progress is being made toward the control of meningococcal infections. This review summarizes current knowledge of the global epidemiology and the pathophysiology of meningococcal disease, as well as recent advances in prevention by new vaccines. Meningococcal disease patterns and incidence can vary dramatically, both geographically and over time in populations, influenced by differences in invasive meningococcal capsular serogroups and specific genotypes designated as ST clonal complexes. Serogroup A (ST-5, ST-7), B (ST-41/44, ST-32, ST-18, ST-269, ST-8, ST-35), C (ST-11), Y (ST-23, ST-167), W-135 (ST-11) and X (ST-181) meningococci currently cause almost all invasive disease. Serogroups B, C, and Y are responsible for the majority of cases in Europe, the Americas, and Oceania; serogroup A has been associated with the highest incidence (up to 1000 per 100,000 cases) and large outbreaks of meningococcal disease in sub-Saharan Africa and previously Asia; and serogroups W-135 and X have emerged to cause major disease outbreaks in sub-Saharan Africa. Significant declines in meningococcal disease have occurred in the last decade in many developed countries. In part, the decline is related to the introduction of new meningococcal vaccines. Serogroup C polysaccharide-protein conjugate vaccines were introduced over a decade ago, first in the UK in a mass vaccination campaign, and are now widely used; multivalent meningococcal conjugate vaccines containing serogroups A, C, W-135, and/or Y were first used for adolescents in the US in 2005 and have now expanded indications for infants and young children, and a new serogroup A conjugate vaccine has recently been introduced in sub-Saharan Africa. The effectiveness of these conjugate vaccines has been enhanced by the prevention of person-to-person transmission and herd immunity. In addition, progress has been made in serogroup B-specific vaccines based on conserved proteins and outer membrane vesicles. However, continued global surveillance is essential in understanding and predicting the dynamic changes in the epidemiology and biological basis of meningococcal disease and to influence the recommendations for current and future vaccines or other prevention strategies.

Citing Articles

An Outbreak of Serogroup Y Meningococcal Meningitis in a Private Secondary Vocational School - Guangzhou City, Guangdong Province, China, 2023.

Zeng X, He Q, Li Y, Zhou Y, Shao X, Hu P China CDC Wkly. 2024; 6(12):242-246.

PMID: 38633428 PMC: 11018515. DOI: 10.46234/ccdcw2024.048.

Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis.

Savitskaya V, Dolinnaya N, Strekalovskikh V, Peskovatskova E, Snyga V, Trefilov V Med Sci (Basel). 2023; 11(4).

PMID: 38132917 PMC: 10744425. DOI: 10.3390/medsci11040076.

Epidemiology and genetic diversity of invasive Neisseria meningitidis strains circulating in Portugal from 2003 to 2020.

Bettencourt C, Nunes A, Nogueira P, Duarte S, Silva C, Gomes J Int Microbiol. 2023; 27(4):1125-1136.

PMID: 38057459 PMC: 11300501. DOI: 10.1007/s10123-023-00463-w.

Real-world impact and effectiveness of MenACWY-TT.

Villena R, Kriz P, Htar M, Burman C, Findlow J, Balmer P Hum Vaccin Immunother. 2023; 19(2):2251825.

PMID: 37679903 PMC: 10486281. DOI: 10.1080/21645515.2023.2251825.

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.

Ispasanie E, Muri L, Schmid M, Schubart A, Thorburn C, Zamurovic N Front Immunol. 2023; 14:1180833.

PMID: 37457736 PMC: 10349132. DOI: 10.3389/fimmu.2023.1180833.

References

Boisier P, Nicolas P, Djibo S, Taha M, Jeanne I, Mainassara H . Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007; 44(5):657-63. DOI: 10.1086/511646. View

Greenwood B, Bradley A, Wall R . Meningococcal disease and season in sub-Saharan Africa. Lancet. 1985; 2(8459):829-30. DOI: 10.1016/s0140-6736(85)90812-8. View

Tsang R, Henderson A, Cameron M, Tyler S, Tyson S, Law D . Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol. 2007; 45(6):1753-8. PMC: 1933026. DOI: 10.1128/JCM.02134-06. View

Harrison L, Shutt K, Schmink S, Marsh J, Harcourt B, Wang X . Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. J Infect Dis. 2010; 201(8):1208-24. PMC: 2838939. DOI: 10.1086/651505. View

Tzeng Y, Datta A, Ambrose K, Lo M, Davies J, Carlson R . The MisR/MisS two-component regulatory system influences inner core structure and immunotype of lipooligosaccharide in Neisseria meningitidis. J Biol Chem. 2004; 279(33):35053-62. DOI: 10.1074/jbc.M401433200. View

Gagneux S, Wirth T, Hodgson A, Ehrhard I, Morelli G, Kriz P . Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis. 2002; 8(5):462-6. PMC: 2732495. DOI: 10.3201/eid0805.010227. View

Deutch S, Labouriau R, Schonheyeder H, Ostergaard L, Norgard B, Sorensen H . Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study. Scand J Infect Dis. 2004; 36(1):20-3. DOI: 10.1080/00365540310017500. View

Perrocheau A, Meffre C, Hahne S . Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002; 8(8):761-7. PMC: 2732506. DOI: 10.3201/eid0808.010422. View

Stephens D, Greenwood B, Brandtzaeg P . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580):2196-2210. DOI: 10.1016/S0140-6736(07)61016-2. View

10.

Richmond P, Marshall H, Nissen M, Jiang Q, Jansen K, Garces-Sanchez M . Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(8):597-607. DOI: 10.1016/S1473-3099(12)70087-7. View

11.

McCoy R, Vimr E, Troy F . CMP-NeuNAc:poly-alpha-2,8-sialosyl sialyltransferase and the biosynthesis of polysialosyl units in neural cell adhesion molecules. J Biol Chem. 1985; 260(23):12695-9. View

12.

Raghunathan P, Jones J, Tiendrebeogo S, Sanou I, Sangare L, Kouanda S . Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J Infect Dis. 2006; 193(5):607-16. DOI: 10.1086/499822. View

13.

Westendorp R, Langermans J, Huizinga T, Elouali A, Verweij C, Boomsma D . Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997; 349(9046):170-3. DOI: 10.1016/s0140-6736(96)06413-6. View

14.

Kertesz D, Coulthart M, Ryan J, Johnson W, Ashton F . Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J Infect Dis. 1998; 177(6):1754-7. DOI: 10.1086/517439. View

15.

Westendorp R, Langermans J, de Bel C, Meinders A, Vandenbroucke J, Van Furth R . Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis. 1995; 171(4):1057-60. DOI: 10.1093/infdis/171.4.1057. View

16.

Hammerschmidt S, Muller A, Sillmann H, Muhlenhoff M, Borrow R, Fox A . Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol. 1996; 20(6):1211-20. DOI: 10.1111/j.1365-2958.1996.tb02641.x. View

17.

Bishai D, Champion C, Steele M, Thompson L . Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood). 2011; 30(6):1058-64. DOI: 10.1377/hlthaff.2011.0295. View

18.

Delrieu I, Yaro S, Tamekloe T, Njanpop-Lafourcade B, Tall H, Jaillard P . Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 2011; 6(5):e19513. PMC: 3098835. DOI: 10.1371/journal.pone.0019513. View

19.

Alcala B, Arreaza L, Salcedo C, Uria M, de la Fuente L, Vazquez J . Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis. 2002; 8(12):1512-4. PMC: 2738524. DOI: 10.3201/eid0812.020081. View

20.

Halperin S, Gupta A, Jeanfreau R, Klein N, Reisinger K, Walter E . Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010; 28(50):7865-72. DOI: 10.1016/j.vaccine.2010.09.092. View